NCT04059991

Antibodies in Repeated Influenza Vaccination (ARIVA) Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 150 (actual)
• Sponsor: University Hospital, Basel, Switzerland · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Viruses with high mutation rates, such influenza or HIV, pose a major challenge for vaccine design. The current influenza vaccination strategy of yearly vaccination with adapted strains aims to maximally diversify the antibody immune response to prevent viral escape. There is, however, growing evidence, that repeated vaccination with very similar viral proteins might limit, instead of broaden, diversification and thereby reduce vaccine efficacy. The ARIVA Study prospectively studies the immunological impact of repeated influenza vaccination on viral variant recognition and antibody responses in healthy subjects cross-sectionally and over three consecutive vaccination seasons.

Conditions

• Vaccine Response Impaired

Interventions

Type	Name	Description
BIOLOGICAL	Influenza Vaccination	Only subjects vaccinated against influenza will be enrolled. The study itself is observational

Timeline

• Start date: 2017-11-01
• Primary completion: 2021-03-31
• Completion: 2021-03-31
• First posted: 2019-08-16
• Last updated: 2021-09-28

Locations

1 site across 1 country: Switzerland